

# Mohammad I Saleh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5450125/publications.pdf>

Version: 2024-02-01

24  
papers

191  
citations

1162367

8  
h-index

1125271

13  
g-index

24  
all docs

24  
docs citations

24  
times ranked

216  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics of Ibrutinib in Healthy Adults. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 405-413.	0.6	0
2	Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. <i>Drug Research</i> , 2021, 71, 429-437.	0.7	2
3	A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1267-1280.	1.1	20
4	Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 31-42.	0.6	1
5	A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. <i>Journal of Chemotherapy</i> , 2019, 31, 274-283.	0.7	1
6	Clarithromycin laurate salt: physicochemical properties and pharmacokinetics after oral administration in humans. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 607-615.	1.1	2
7	Patient characteristics associated with pegylated interferon alfa-2a induced neutropenia in chronic hepatitis C patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 636-642.	0.9	4
8	Evaluation of the impact of waterpipe tobacco smoke exposure on the activity and expression of rat hepatic CYP450: a pharmacokinetic study. <i>Inhalation Toxicology</i> , 2018, 30, 519-526.	0.8	3
9	Population pharmacokinetics of vancomycin in Jordanian patients. <i>Tropical Journal of Pharmaceutical Research</i> , 2018, 17, 351.	0.2	1
10	Predictors of nonadherence in children and adolescents with epilepsy: A multimethod assessment approach. <i>Epilepsy and Behavior</i> , 2018, 85, 205-211.	0.9	12
11	A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 953-963.	1.4	2
12	Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection. <i>American Journal of Therapeutics</i> , 2017, 24, e670-e675.	0.5	4
13	A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon $\alpha$ -2a in Hepatitis C Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1369-1379.	1.6	5
14	Clinical Predictors Associated With Warfarin Sensitivity. <i>American Journal of Therapeutics</i> , 2016, 23, e1690-e1694.	0.5	9
15	Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 86-92.	0.8	28
16	Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 1030-1035.	0.9	6
17	Modeling Longitudinal Changes in Buprenorphine Treatment Outcome for Opioid Dependence. <i>Pharmacopsychiatry</i> , 2014, 47, 251-258.	1.7	4
18	Dosage Individualization of Warfarin Using Artificial Neural Networks. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 371-379.	1.6	25

#	ARTICLE	IF	CITATIONS
19	Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine. <i>European Review for Medical and Pharmacological Sciences</i> , 2014, 18, 3935-42.	0.5	4
20	Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2013, 304, R772-R781.	0.9	15
21	Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [ <sup>14</sup> C]cyanate: validation of a model to study human physiology and disease. <i>Transfusion</i> , 2012, 52, 963-973.	0.8	5
22	Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 131-139.	1.1	5
23	Correction for effect of cold storage on immature platelet fraction. <i>Journal of Clinical Laboratory Analysis</i> , 2010, 24, 431-433.	0.9	10
24	Evidence of Receptor-Mediated Elimination of Erythropoietin by Analysis of Erythropoietin Receptor mRNA Expression in Bone Marrow and Erythropoietin Clearance During Anemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 528-532.	1.3	23